These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 24186139)

  • 1. Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancers.
    Yoshida A; Tsuta K; Wakai S; Arai Y; Asamura H; Shibata T; Furuta K; Kohno T; Kushima R
    Mod Pathol; 2014 May; 27(5):711-20. PubMed ID: 24186139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases.
    Yoshida A; Kohno T; Tsuta K; Wakai S; Arai Y; Shimada Y; Asamura H; Furuta K; Shibata T; Tsuda H
    Am J Surg Pathol; 2013 Apr; 37(4):554-62. PubMed ID: 23426121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
    Mescam-Mancini L; Lantuéjoul S; Moro-Sibilot D; Rouquette I; Souquet PJ; Audigier-Valette C; Sabourin JC; Decroisette C; Sakhri L; Brambilla E; McLeer-Florin A
    Lung Cancer; 2014 Feb; 83(2):168-73. PubMed ID: 24380695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers for ALK and ROS1 in Lung Cancer: Immunohistochemistry and Fluorescent In Situ Hybridization.
    Luk PP; Selinger CI; Mahar A; Cooper WA
    Arch Pathol Lab Med; 2018 Aug; 142(8):922-928. PubMed ID: 29902067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ROS1 copy number alterations are frequent in non-small cell lung cancer.
    Clavé S; Gimeno J; Muñoz-Mármol AM; Vidal J; Reguart N; Carcereny E; Pijuan L; Menéndez S; Taus Á; Mate JL; Serrano S; Albanell J; Espinet B; Arriola E; Salido M
    Oncotarget; 2016 Feb; 7(7):8019-28. PubMed ID: 26783962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ROS1 rearrangements in lung adenocarcinomas are defined by diffuse strong immunohistochemical expression of ROS1.
    Fielder T; Butler J; Tierney G; Holmes M; Lam KY; Satgunaseelan L; Colebatch AJ; Mahar A; Gupta R; O'Toole S; Cooper WA
    Pathology; 2022 Jun; 54(4):399-403. PubMed ID: 34702583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target.
    Selinger CI; Li BT; Pavlakis N; Links M; Gill AJ; Lee A; Clarke S; Tran TN; Lum T; Yip PY; Horvath L; Yu B; Kohonen-Corish MR; O'Toole SA; Cooper WA
    Histopathology; 2017 Feb; 70(3):402-411. PubMed ID: 27599111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of ROS1-positive non-small cell lung cancer on cytological specimens using immunocytochemistry.
    Vlajnic T; Savic S; Barascud A; Baschiera B; Bihl M; Grilli B; Herzog M; Rebetez J; Bubendorf L
    Cancer Cytopathol; 2018 Jun; 126(6):421-429. PubMed ID: 29451745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.
    Kim HR; Lim SM; Kim HJ; Hwang SK; Park JK; Shin E; Bae MK; Ou SH; Wang J; Jewell SS; Kang DR; Soo RA; Haack H; Kim JH; Shim HS; Cho BC
    Ann Oncol; 2013 Sep; 24(9):2364-70. PubMed ID: 23788756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter Evaluation of a Novel ROS1 Immunohistochemistry Assay (SP384) for Detection of ROS1 Rearrangements in a Large Cohort of Lung Adenocarcinoma Patients.
    Hofman V; Rouquette I; Long-Mira E; Piton N; Chamorey E; Heeke S; Vignaud JM; Yguel C; Mazières J; Lepage AL; Bibeau F; Begueret H; Lassalle S; Lalvée S; Zahaf K; Benzaquen J; Poudenx M; Marquette CH; Sabourin JC; Ilié M; Hofman P
    J Thorac Oncol; 2019 Jul; 14(7):1204-1212. PubMed ID: 30999109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a Dual ALK/ROS1 Fluorescent In Situ Hybridization Test in Non-Small-cell Lung Cancer.
    Ginestet F; Lambros L; Le Flahec G; Marcorelles P; Uguen A
    Clin Lung Cancer; 2018 Sep; 19(5):e647-e653. PubMed ID: 29801706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma.
    Lee SE; Lee B; Hong M; Song JY; Jung K; Lira ME; Mao M; Han J; Kim J; Choi YL
    Mod Pathol; 2015 Apr; 28(4):468-79. PubMed ID: 25234288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytological findings of ROS1-rearranged lung adenocarcinoma.
    Kuroda N; Tamiya H; Nakatani K; Ide H; Wada Y; Yasuoka K; Ohara M; Mizuno K; Yorita K; Takeuchi K
    Diagn Cytopathol; 2018 Apr; 46(4):336-339. PubMed ID: 29076659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histopathologic characteristics of advanced-stage ROS1-rearranged non-small cell lung cancers.
    Park E; Choi YL; Ahn MJ; Han J
    Pathol Res Pract; 2019 Jul; 215(7):152441. PubMed ID: 31085007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A genomic and clinicopathological study of non-small-cell lung cancers with discordant ROS1 gene status by fluorescence in-situ hybridisation and immunohistochemical analysis.
    Zhao J; Chen X; Zheng J; Kong M; Wang B; Ding W
    Histopathology; 2018 Jul; 73(1):19-28. PubMed ID: 29464758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas.
    Sholl LM; Sun H; Butaney M; Zhang C; Lee C; Jänne PA; Rodig SJ
    Am J Surg Pathol; 2013 Sep; 37(9):1441-9. PubMed ID: 23887156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Canadian ROS proto-oncogene 1 study (CROS) for multi-institutional implementation of ROS1 testing in non-small cell lung cancer.
    Cheung CC; Smith AC; Albadine R; Bigras G; Bojarski A; Couture C; Cutz JC; Huang WY; Ionescu D; Itani D; Izevbaye I; Karsan A; Kelly MM; Knoll J; Kwan K; Nasr MR; Qing G; Rashid-Kolvear F; Sekhon HS; Spatz A; Stockley T; Tran-Thanh D; Tucker T; Waghray R; Wang H; Xu Z; Yatabe Y; Torlakovic EE; Tsao MS
    Lung Cancer; 2021 Oct; 160():127-135. PubMed ID: 34509095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion.
    Rimkunas VM; Crosby KE; Li D; Hu Y; Kelly ME; Gu TL; Mack JS; Silver MR; Zhou X; Haack H
    Clin Cancer Res; 2012 Aug; 18(16):4449-57. PubMed ID: 22661537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ROS1 rearrangements define a unique molecular class of lung cancers.
    Bergethon K; Shaw AT; Ou SH; Katayama R; Lovly CM; McDonald NT; Massion PP; Siwak-Tapp C; Gonzalez A; Fang R; Mark EJ; Batten JM; Chen H; Wilner KD; Kwak EL; Clark JW; Carbone DP; Ji H; Engelman JA; Mino-Kenudson M; Pao W; Iafrate AJ
    J Clin Oncol; 2012 Mar; 30(8):863-70. PubMed ID: 22215748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequent aerogenous spread with decreased E-cadherin expression of ROS1-rearranged lung cancer predicts poor disease-free survival.
    Jin Y; Sun PL; Park SY; Kim H; Park E; Kim G; Cho S; Kim K; Lee CT; Chung JH
    Lung Cancer; 2015 Sep; 89(3):343-9. PubMed ID: 26149475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.